Kelly Chibale: learning to fail your way to success (Publications)
A portrait is given of Professor Kelly Chibale, the driving force behind H3D, the drug discovery and development centre at the University of Cape Town, South Africa. He is dedicated to the development
Basel: a hotspot for drug discovery and development against poverty-related diseases (Publications)
In discussion with Lukas Meier from the Swiss Tropical and Public Health Institute (Swiss TPH), Lutz Hegemann, Head of Novartis Global Health and Sustainability and Marcel Tanner, President of the Swi
Repurposing of tuberculosis drug candidates for the treatment of <em>Mycobacterium ulcerans</em> disease (Publications)
Buruli ulcer (BU) is a chronic necrotizing skin disease caused by Mycobacterium ulcerans. Historically, the disease was treated by surgical excision of the skin lesions, until an 8-week combination th
Quinacrine - the winding road from the most important antimalarial of its time to an indispensable antiparasitic (orphan) drug of our days (Publications)
Quinacrine, the main antimalarial drug during World War II, has had a chequered history that included the successful repurposing as an intrapleural sclerosant for the treatment of malignant pleural ef
Repurposing know-how for drug development: case studies from the Swiss Tropical and Public Health Institute (Publications)
In pursuing novel therapeutic solutions, drug discovery and development rely on efficiently utilising existing knowledge and resources. Repurposing know-how, a strategy that capitalises on previously
Key contributions by the Swiss Tropical and Public Health Institute towards new and better drugs for tropical diseases (Publications)
Thanks to its expertise in clinical research, epidemiology, infectious diseases, microbiology, parasitology, public health, translational research and tropical medicine, coupled with deeply rooted par
Hepatitis B and C in Europe: an update from the Global Burden of Disease Study 2019 (Publications)
BACKGROUND: In 2016, the World Health Assembly adopted the resolution to eliminate viral hepatitis by 2030. This study aims to provide an overview of the burdens of hepatitis B virus (HBV) and hepatit
Operational differences between product development partnership, pharmaceutical industry, and investigator initiated clinical trials (Publications)
Medicine development is a lengthy endeavour. Increasing regulatory stringency and trial complexity might lead to reduced efficiency, dwindled output, and elevated costs. However, alternative models ar
Impact of population aging on future temperature-related mortality at different global warming levels (Publications)
Older adults are generally amongst the most vulnerable to heat and cold. While temperature-related health impacts are projected to increase with global warming, the influence of population aging on th